Cargando…
Risks of Stroke and Mortality in Atrial Fibrillation Patients Treated With Rivaroxaban and Warfarin
Oral anticoagulation therapy is standard of care for patients with nonvalvular atrial fibrillation to prevent stroke. This study compared rivaroxaban and warfarin for stroke and all-cause mortality risk reduction in a real-world setting. METHODS—: This retrospective cohort study (2011–2017) included...
Autores principales: | Alberts, Mark, Chen, Yen-Wen, Lin, Jennifer H., Kogan, Emily, Twyman, Kathryn, Milentijevic, Dejan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004448/ https://www.ncbi.nlm.nih.gov/pubmed/31888412 http://dx.doi.org/10.1161/STROKEAHA.119.025554 |
Ejemplares similares
-
Assessing stroke severity using electronic health record data: a machine learning approach
por: Kogan, Emily, et al.
Publicado: (2020) -
Rivaroxaban Versus Warfarin for Management of Obese African Americans
With Non-Valvular Atrial Fibrillation or Venous Thromboembolism: A Retrospective
Cohort Analysis
por: Costa, Olivia S., et al.
Publicado: (2020) -
Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
por: Kim, Hyunmee, et al.
Publicado: (2018) -
Effectiveness and Safety of Rivaroxaban versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Polypharmacy
por: Alberts, Mark J., et al.
Publicado: (2022) -
Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)